What is Virometix?
Virometix AG is a clinical-stage biotechnology firm dedicated to pioneering a new generation of synthetic vaccines designed to combat infectious diseases. Leveraging a proprietary modular nanoparticle technology, their platform aims to generate precise and enduring immune responses, offering a safe, cost-effective, and scalable approach to vaccine development. The company is actively advancing a pipeline of vaccine candidates, including a novel serotype-independent vaccine for Streptococcus pneumoniae and epitope-specific vaccines targeting Respiratory Syncytial Virus. Virometix AG is positioned to address critical unmet medical needs in infectious disease prevention for healthcare providers and global health organizations.
How much funding has Virometix raised?
Virometix has raised a total of $28.1M across 3 funding rounds:
Series A
$5.1M
Series B
$7.9M
Unspecified
$15M
Series A (2017): $5.1M, investors not publicly disclosed
Series B (2020): $7.9M, investors not publicly disclosed
Unspecified (2025): $15M, investors not publicly disclosed
What's next for Virometix?
The substantial enterprise-level funding indicates Virometix AG is poised for significant scaling and advancement of its clinical pipeline. This capital injection is expected to accelerate the development and regulatory pathways for its innovative vaccine candidates, particularly the Streptococcus pneumoniae and RSV vaccines. The strategic nature of the recent investment suggests strong alignment with partners focused on long-term growth and market penetration in the infectious disease prevention sector. Future endeavors will likely concentrate on expanding clinical trials, securing manufacturing capabilities, and forging strategic partnerships to bring these advanced vaccine solutions to a global market.
See full Virometix company page
